BioDelivery Sciences to present at Cowen and ROTH conferences (PRNewswire) - Mar 5, 2012 - BDSI, will present at each conference with focus on the clinical development program and timeline for BEMA buprenorphine/naloxone (BNX) for the treatment of opioid dependence as well as the recent licensing and development agreement with Endo Pharmaceuticals for BEMA buprenorphine for the treatment of chronic pain
Anticipated corporate presentation • Pain
|
|
RALEIGH, N.C., March 5, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced its participation at two upcoming investor conferences. Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at each conference where he will focus on the clinical development program and timeline for BEMA Buprenorphine/Naloxone (BNX) for the treatment of opioid dependence as well as the recent licensing and development agreement with Endo Pharmaceuticals for BEMA Buprenorphine for the treatment of chronic pain.
Cowen and Company 32nd Annual Health Care Conference
Wednesday, March 7 at 9:20 AM Eastern Time
Boston Marriott Copley Place, Boston, MA
24th Annual ROTH Conference
Tuesday, March 13 at 12:00 PM Pacific Time (3:00 PM Eastern)
Ritz Carlton Laguna Niguel, Dana Point, CA
|